Publications by authors named "Roy S Herbst"

290Publications

Introduction by the Guest Editors.

Cancer J 2020 Nov/Dec;26(6):471-472

From the Department of Medicine (Medical Oncology), Yale School of Medicine, New Haven, CT.

View Article and Find Full Text PDF
December 2020

Clearing the Haze: What Do We Still Need to Learn about Electronic Nicotine Delivery Systems?

Cancer Prev Res (Phila) 2020 Nov 3. Epub 2020 Nov 3.

Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.

View Article and Find Full Text PDF
November 2020

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.

N Engl J Med 2020 10;383(14):1328-1339

From the Yale School of Medicine, New Haven, CT (R.S.H.); Weill Cornell Medical Center, New York (G.G.); the European Institute of Oncology, IRCCS, Milan (F.M.); Asklepios Lung Clinic, Munich-Gauting, Germany (N.R.); University Hospital Limoges, Limoges, France (A.V.); Centro de Pesquisa Clínica, Hospital São Lucas, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil (C.H.B.); Nagoya University Graduate School of Medicine, Aichi, Japan (M. Morise); Vall d'Hebron University Hospital, Barcelona (E.F.); Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia (Z.A.); Prince of Songkla University-Hat Yai, Songkhla, Thailand (S.G.); Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Istanbul, Turkey (M.O.); Genentech, South San Francisco, CA (W.Z., A.S., I.E., K.K., Y.D., H.K., X.W., M. McCleland, S.M.); the Medical University of Gdańsk, Gdansk, Poland (J.J.); and the Sarah Cannon Research Institute at Tennessee Oncology, Nashville (D.R.S.).

View Article and Find Full Text PDF
October 2020

Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.

N Engl J Med 2020 10 19;383(18):1711-1723. Epub 2020 Sep 19.

From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), the Thoracic Surgery Department, National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), and the Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai (S.L.) - all in China; the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), and the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Department of Medical Oncology, Austin Health, Melbourne, VIC, Australia (T.J.); the Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin (C.G.); the Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and the Department of Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.W.G.); the Center of Innovative Technologies and Oncology, N.N. Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow (K.L.); the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (S.-W.K.), and the Precision Medicine Lung Cancer Center, Konkuk University Medical Center (K.-Y.L.) - both in Seoul, South Korea; the Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam (H.-V.V.); the Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand (C.A.); the Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-J.Y.); the Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan (F.M.), and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua (L.B.) - both in Italy; the Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto (F.A.S.); Late Oncology Statistics, AstraZeneca, Gaithersburg, MD (L.Z.); Late Oncology Statistics (R.H.) and Oncology Research and Development (A.A., Y.R.), AstraZeneca, Cambridge, United Kingdom; and Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.).

View Article and Find Full Text PDF
October 2020

Frontline immunotherapy for NSCLC - the tale of the tail.

Nat Rev Clin Oncol 2020 02;17(2):73-74

Department of Internal Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.

View Article and Find Full Text PDF
February 2020

Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy.

Clin Cancer Res 2020 02 15;26(4):970-977. Epub 2019 Oct 15.

Department of Pathology, Yale University School of Medicine, New Haven, Connecticut.

View Article and Find Full Text PDF
February 2020

Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.

J Thorac Oncol 2019 12 9;14(12):2084-2096. Epub 2019 Oct 9.

Department of Pathology, Yale University School of Medicine, New Haven, Connecticut; Department of Medicine (Oncology), Yale University School of Medicine, New Haven, Connecticut. Electronic address:

View Article and Find Full Text PDF
December 2019